BioLargo (BLGO) Changes Certifying Accountant on Jan 2
Ticker: BLGO · Form: 8-K · Filed: Jan 5, 2024 · CIK: 880242
Complexity: simple
Sentiment: neutral
Topics: auditor-change, corporate-governance, 8-K
TL;DR
**BLGO just switched auditors, keep an eye on their next financial reports.**
AI Summary
BioLargo, Inc. (BLGO) announced on January 2, 2024, that it has changed its certifying accountant, a significant event for investors. This change, reported in an 8-K filing on January 5, 2024, means a new firm will be auditing their financial statements. For shareholders, this matters because the integrity and reliability of a company's financial reporting are crucial for making informed investment decisions, and a change in auditors can sometimes signal underlying issues or a fresh start.
Why It Matters
A change in a company's auditor can impact investor confidence, as auditors are responsible for ensuring the accuracy and reliability of financial statements.
Risk Assessment
Risk Level: medium — Changing auditors can sometimes indicate disagreements over accounting practices or a need for a fresh perspective, which introduces a moderate level of uncertainty.
Analyst Insight
Investors should monitor BioLargo's upcoming financial statements closely for any changes in reporting quality or restatements, and research the new auditing firm's reputation.
Key Players & Entities
- BioLargo, Inc. (company) — the registrant filing the 8-K
- January 2, 2024 (date) — date of the earliest event reported (change in accountant)
- January 5, 2024 (date) — date the 8-K filing was made
- BLGO (company) — trading symbol for BioLargo, Inc.
FAQ
What was the specific event reported by BioLargo, Inc. in this 8-K filing?
BioLargo, Inc. reported a 'Changes in Registrant's Certifying Accountant' as the specific event, with the earliest event reported date being January 2, 2024.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted to the SEC on January 5, 2024, as indicated by the 'FILED AS OF DATE: 20240105'.
What is BioLargo, Inc.'s trading symbol and on which exchange is its common stock registered?
BioLargo, Inc.'s trading symbol is BLGO, and its common stock is registered on the OTCQB exchange, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address and phone number of BioLargo, Inc.?
BioLargo, Inc.'s business address is 14921 Chestnut St., Westminster, California, 92683, and its business phone number is (888) 400-2863.
What is the company's Central Index Key (CIK) and SEC File Number?
BioLargo, Inc.'s Central Index Key (CIK) is 0000880242, and its SEC File Number is 000-19709.
Filing Stats: 733 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-01-05 13:05:46
Filing Documents
- blgo20240104_8k.htm (8-K) — 29KB
- ex_612250.htm (EX-16.1) — 4KB
- footer.jpg (GRAPHIC) — 9KB
- logo.jpg (GRAPHIC) — 7KB
- signature.jpg (GRAPHIC) — 4KB
- 0001437749-24-000717.txt ( ) — 188KB
- blgo-20240102.xsd (EX-101.SCH) — 3KB
- blgo-20240102_def.xml (EX-101.DEF) — 11KB
- blgo-20240102_lab.xml (EX-101.LAB) — 14KB
- blgo-20240102_pre.xml (EX-101.PRE) — 11KB
- blgo20240104_8k_htm.xml (XML) — 2KB
01 Changes in Registrant ' s Certifying Accountant
Item 4.01 Changes in Registrant ' s Certifying Accountant.   (a) On January 2, 2024, the Audit Committee (the "Committee") of the Board of Directors of BioLargo, Inc. (the "Company") approved the engagement of Hacker Johnson & Smith PA ("Hacker Johnson") as the Company's independent registered public accounting firm for the Company's fiscal year ended December 31, 2023, effective immediately, and dismissed Haskell & White LLP ("Haskell & White"), as the Company's independent registered public accounting firm.   During the fiscal years ended December 31, 2022, and 2021, and the subsequent interim periods through January 2, 2024, there were (i) no disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Haskell & White on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Haskell & White's satisfaction, would have caused Haskell & White to make reference thereto in their reports on the financial statements for such years, and (ii) no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K.   The Company has provided a copy of the foregoing disclosures to Haskell & White and requested that Haskell & White furnish it with a letter addressed to the Securities and Exchange Commission stating whether Haskell & White agrees with the above statements. A copy of Haskell & White's letter, dated January 3, 2024, is filed as Exhibit 16.1 to this Form 8-K.   (b) During the two most recent fiscal years and in the subsequent interim period through January 2, 2024, neither the Company nor anyone acting on its behalf has consulted with Hacker Johnson with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that would have been rendered on the Company's consolidated financial statements, or any oth
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.      (d) Exhibits.       Exhibit No.   Description 16.1 Letter from Haskell & White LLP to the Securities and Exchange Commission dated January 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)    
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: January 5, 2024 BIOLARGO, INC. By: /s/  Dennis P. Calvert Dennis P. Calvert President and Chief Executive Officer